Please ensure Javascript is enabled for purposes of website accessibility

Why Wall Street Wasn't Bothered by Jazz Pharmaceuticals' Mixed Q4 Results

By Keith Speights - Feb 24, 2021 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company beat top-line estimates, but missed on the bottom line.

The biggest news for Jazz Pharmaceuticals (JAZZ -1.47%) in recent months was the company's announcement earlier this month that it plans to acquire GW Pharmaceuticals in a $7.6 billion deal. Investors initially weren't very thrilled with the acquisition, but later seemed to view it in a more positive light.

Now, Jazz has more news that investors eagerly awaited. The drugmaker announced its fourth-quarter results after the market closed on Tuesday. Here are the highlights from Jazz's Q4 update.

Pills shaped as dollar signs in medication packaging.

Image source: Getty Images.

By the numbers

Jazz reported revenue in the fourth quarter of $665.5 million. This reflected a 14% increase from the prior-year period revenue total of $581.7 million. It also topped the Wall Street consensus estimate of $639.55 million.

The company announced net income of $133.4 million, or $2.33 per share, based on generally accepted accounting principles (GAAP). In the prior-year period, Jazz posted GAAP earnings of $74 million, or $1.29 per share. 

Jazz recorded adjusted net income in the fourth quarter of $228.7 million, or $4.0 per share, down from $253.2 million, or $4.42 per share, in the same period in 2019. It was also well below analysts' average adjusted earnings estimate of $4.20 per share.

Behind the numbers

Sleep disorder drug Xyrem remained Jazz's biggest moneymaker in Q4. Sales for the drug rose 1% year over year to $439.3 million. Its successor, Xywav, launched in the U.S. in November and generated sales of $15.3 million in the fourth quarter. 

Jazz also launched small cell lung cancer drug Zepzelca in July 2020. Sales for the drug totaled $54.4 million in Q4. Sales for another relatively new narcolepsy drug, Sunosi, which launched in July 2019, came in at $8.7 million in Q4, up from $2.7 million in the prior-year period.

Defitelio/defibrotide, which is approved to treat liver disorder veno-occlusive disease, generated sales of $55.5 million in Q4, a 16% year-over-year jump. Sales for leukemia drug Erwinaze/Erwinase rose 3% to $55.6 million. Manufacturing issues at Porton Biopharma Limited continued to limit the availability of the supply of the drug.

Jazz's worst performance in the fourth quarter came from another leukemia drug, Vyxeos. Sales for the drug fell 2% year over year to $31 million, largely due to the impact of the COVID-19 pandemic.

The company's bottom line in Q4 was weighed down in large part by increased expenses related to the launches of Zepzelca and Xywav and the continued rollout of Sunosi. In addition, Jazz made an upfront payment of $35 million to purchase SpringWorks Therapeutics' fatty acid amide hydrolase (FAAH) inhibitor program.

Looking ahead

Investors didn't seem concerned about Jazz's mixed Q4 results, with shares rising slightly in after-hours trading. That's probably because Jazz looks for solid growth going forward.

The company projects full-year 2021 revenue of between $2.55 billion and $2.7 billion, with net product sales in the range of $2.54 billion to $2.685 billion. It anticipates GAAP earnings per share for the year will be between $8.30 and $10.45, with adjusted earnings per share between $15.65 and $16.85.

Jazz looks for the acquisition of GW Pharmaceuticals to close in the second quarter of this year. The deal should enable Jazz to achieve double-digit revenue growth.

Other potential catalysts on the way for the biotech stock relate to its lead sleep disorder candidate. Jazz plans to report late-stage results for JZP-258 in Q2, with an anticipated launch in the fourth quarter of this year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Jazz Pharmaceuticals plc Stock Quote
Jazz Pharmaceuticals plc
JAZZ
$150.22 (-1.47%) $-2.24
GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
GWPH

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.